Observations with Bazoton in the management of prostatic hyperplasia.
Thirty patients with prostatic hyperplasia stages I and II were administered Bazoton capsules (extract of Radix Urticae) for an average period of 3.5 months. Residual urine, mean and maximal flow were measured before and after treatment. A significant decrease in the volume of residual urine was found. Increase in mean urinary flow was also significant. Maximal urinary flow increased in 50% of the cases. A marked subjective relief was reported by the patients. Bazoton is regarded as suitable for the conservative treatment of prostatic hyperplasia stages I and II.
D006801:Humans; D008297:Male; D008875:Middle Aged; D010936:Plant Extracts / Q000627:therapeutic use*; D011470:Prostatic Hyperplasia / Q000188:drug therapy*
D010936:Plant Extracts; C033043:Bazoton